MA63861A1 - Composition pharmaceutique de virus non enveloppé - Google Patents

Composition pharmaceutique de virus non enveloppé

Info

Publication number
MA63861A1
MA63861A1 MA63861A MA63861A MA63861A1 MA 63861 A1 MA63861 A1 MA 63861A1 MA 63861 A MA63861 A MA 63861A MA 63861 A MA63861 A MA 63861A MA 63861 A1 MA63861 A1 MA 63861A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
enveloped virus
compositions
virus
enveloped
Prior art date
Application number
MA63861A
Other languages
English (en)
Inventor
Ekaterina Aleksandrovna LOMKOVA
Dmitry Valentinovich MOROZOV
Aleksandr Olegovich IAKOVLEV
Aleksandra Aleksandrovna SOZONOVA
Lina Igorevna FEDORENKO
Marina Konstantinovna DVORIANKINA
Original Assignee
Joint Stock Company "Biocad"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2021120143A/ru
Application filed by Joint Stock Company "Biocad" filed Critical Joint Stock Company "Biocad"
Publication of MA63861A1 publication Critical patent/MA63861A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le domaine des produits pharmaceutiques, de la thérapie génique et de la médecine, spécifiquement des compositions pharmaceutiques d'un vecteur à base de virus recombinant non enveloppé, en particulier le virus adéno-associé recombinant (rAAV), lesquelles compositions peuvent être des compositions aqueuses ou lyophilisées et peuvent être utilisées pour le traitement et la prévention de diverses maladies.
MA63861A 2021-07-08 2022-07-04 Composition pharmaceutique de virus non enveloppé MA63861A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021120143A RU2021120143A (ru) 2021-07-08 Фармацевтическая композиция безоболочечного вируса
PCT/RU2022/050212 WO2023282796A2 (fr) 2021-07-08 2022-07-04 Composition pharmaceutique de virus non enveloppé

Publications (1)

Publication Number Publication Date
MA63861A1 true MA63861A1 (fr) 2024-10-31

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63861A MA63861A1 (fr) 2021-07-08 2022-07-04 Composition pharmaceutique de virus non enveloppé

Country Status (12)

Country Link
EP (1) EP4367252A4 (fr)
CN (1) CN117999353A (fr)
AR (1) AR126417A1 (fr)
CL (1) CL2024000062A1 (fr)
CO (1) CO2024000073A2 (fr)
CR (1) CR20240004A (fr)
EC (1) ECSP24001599A (fr)
JO (1) JOP20240003A1 (fr)
MA (1) MA63861A1 (fr)
MX (1) MX2024000472A (fr)
WO (1) WO2023282796A2 (fr)
ZA (1) ZA202400124B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322162A (en) * 2023-01-19 2025-09-01 Uniqure Biopharma B V Pharmaceutical formulations for the delivery of gene carriers
WO2025051970A2 (fr) * 2023-09-06 2025-03-13 Dinaqor Ag Méthodes de traitement de la cardiomyopathie hypertrophique avec des vecteurs de thérapie génique vaa et des formulations thérapeutiques
WO2025114524A1 (fr) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations pour produits médicamenteux viraux
WO2025263459A1 (fr) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 Composition biopharmaceutique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116280A2 (fr) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations utiles pour vaccins préparés par séchage par atomisation
WO2015040002A1 (fr) * 2013-09-19 2015-03-26 Crucell Holland B.V. Formulations d'adénovirus améliorées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
IL266264B2 (en) * 2016-11-04 2023-11-01 Baxalta Inc Adeno-associated virus formulations
MX2021000810A (es) * 2018-07-24 2021-04-28 Voyager Therapeutics Inc Sistemas y metodos para producir formulaciones de terapia genetica.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116280A2 (fr) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations utiles pour vaccins préparés par séchage par atomisation
WO2015040002A1 (fr) * 2013-09-19 2015-03-26 Crucell Holland B.V. Formulations d'adénovirus améliorées

Also Published As

Publication number Publication date
JOP20240003A1 (ar) 2024-01-08
MX2024000472A (es) 2024-02-12
WO2023282796A3 (fr) 2023-02-16
ZA202400124B (en) 2024-11-27
AR126417A1 (es) 2023-10-11
CO2024000073A2 (es) 2024-04-29
ECSP24001599A (es) 2024-02-29
EP4367252A4 (fr) 2025-04-30
EP4367252A2 (fr) 2024-05-15
WO2023282796A2 (fr) 2023-01-12
CR20240004A (es) 2024-06-11
CN117999353A (zh) 2024-05-07
CL2024000062A1 (es) 2024-06-14

Similar Documents

Publication Publication Date Title
MA63861A1 (fr) Composition pharmaceutique de virus non enveloppé
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
MA30779B1 (fr) Comprimes pediatriques de capecitabine
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
EP4008718A4 (fr) Dérivé d'hétéroarylamidopyridinol et composition pharmaceutique le comprenant en tant que principe actif pour prévenir ou traiter une maladie auto-immune
MA39421A (fr) Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes
EP3785718A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie infectieuse de flavivirus
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
MA58093B1 (fr) Nouveaux analogues d'insuline et leurs utilisations
FR2870126A1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP3845516A4 (fr) NOUVEL INHIBITEUR DE HIF-1alfa, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE OCULAIRE ASSOCIÉE À L'ANGIOGENÈSE, CONTENANT CELUI-CI EN TANT QUE PRINCIPE ACTIF
EP4349341A4 (fr) Préparation pharmaceutique pour la prévention ou le traitement de la fibrose pulmonaire
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
EP4098261A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une stéatohépatite non alcoolique
MA62939A1 (fr) Composition pharmaceutique de pembrolizumab et son utilisation
MA58507A1 (fr) Composition pharmaceutique aqueuse de levilimab
EP4501918A4 (fr) Dérivé de 3-phénylisoxazole et composition pharmaceutique pour prévenir ou traiter une maladie oculaire le contenant en tant que principe actif
FR3096579B1 (fr) composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
MA70850A1 (fr) Composition pharmaceutique d'anticorps anti-cd20 et son utilisation
MA27474A1 (fr) Vaccin
GEAP202516788A (en) Pharmaceutical composition of non-enveloped virus
FR3085679B1 (fr) Composes analogues de la squalamine et leur utilisation medicale